Cargando…

Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine

Patient: Male, 78-year-old Final Diagnosis: Acute generalized exanthematous pustulosis (AGEP) Symptoms: Rash Medication:— Clinical Procedure: — Specialty: Allergology • Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem charac...

Descripción completa

Detalles Bibliográficos
Autores principales: Haraszti, Samantha, Sendil, Selin, Jensen, Nichole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592336/
https://www.ncbi.nlm.nih.gov/pubmed/33097683
http://dx.doi.org/10.12659/AJCR.926901
_version_ 1783601166003732480
author Haraszti, Samantha
Sendil, Selin
Jensen, Nichole
author_facet Haraszti, Samantha
Sendil, Selin
Jensen, Nichole
author_sort Haraszti, Samantha
collection PubMed
description Patient: Male, 78-year-old Final Diagnosis: Acute generalized exanthematous pustulosis (AGEP) Symptoms: Rash Medication:— Clinical Procedure: — Specialty: Allergology • Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem characterized by the abrupt onset of numerous small, non-follicular, sterile pustules arising on an erythematous base. AGEP is often associated with medications; however, it has also been connected to various viral infections including cytomegalovirus, parvo-virus B19, and Epstein-Barr virus. Coronavirus disease 2019 (COVID-19) has been associated with a variety of skin findings, including erythematous or patchy rash, urticaria, hives, blisters, petechiae, livedo reticularis, and even AGEP in a patient undergoing treatment with hydroxychloroquine. CASE REPORT: A 78-year-old man with a past medical history of benign prostatic hyperplasia, coronary artery disease, and atrial fibrillation presented with septic shock secondary to a urinary tract infection. On day 7 of treatment with cefepime, he became febrile and developed a pustular rash and persistent hypotension without any respiratory symptoms. Subsequently, he was diagnosed with COVID-19. Skin biopsy of the rash revealed AGEP. CONCLUSIONS: AGEP is an uncommon cutaneous eruption often triggered by medications and viruses. AGEP is thought to be mediated by pro-inflammatory cells and cytokines. This report describes an unusual presentation of AGEP following treatment with cefepime for a urinary tract infection in a 78-year-old man who was found to be positive for SARS-CoV-2 infection, but was not treated with hydroxychloroquine. Although AGEP has been described in association with some viral infections, it is more commonly a drug-associated dermatosis, commonly seen during treatment with antibiotics. As in this case, AGEP usually resolves after discontinuation of the offending antibiotic.
format Online
Article
Text
id pubmed-7592336
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-75923362020-10-28 Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine Haraszti, Samantha Sendil, Selin Jensen, Nichole Am J Case Rep Articles Patient: Male, 78-year-old Final Diagnosis: Acute generalized exanthematous pustulosis (AGEP) Symptoms: Rash Medication:— Clinical Procedure: — Specialty: Allergology • Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem characterized by the abrupt onset of numerous small, non-follicular, sterile pustules arising on an erythematous base. AGEP is often associated with medications; however, it has also been connected to various viral infections including cytomegalovirus, parvo-virus B19, and Epstein-Barr virus. Coronavirus disease 2019 (COVID-19) has been associated with a variety of skin findings, including erythematous or patchy rash, urticaria, hives, blisters, petechiae, livedo reticularis, and even AGEP in a patient undergoing treatment with hydroxychloroquine. CASE REPORT: A 78-year-old man with a past medical history of benign prostatic hyperplasia, coronary artery disease, and atrial fibrillation presented with septic shock secondary to a urinary tract infection. On day 7 of treatment with cefepime, he became febrile and developed a pustular rash and persistent hypotension without any respiratory symptoms. Subsequently, he was diagnosed with COVID-19. Skin biopsy of the rash revealed AGEP. CONCLUSIONS: AGEP is an uncommon cutaneous eruption often triggered by medications and viruses. AGEP is thought to be mediated by pro-inflammatory cells and cytokines. This report describes an unusual presentation of AGEP following treatment with cefepime for a urinary tract infection in a 78-year-old man who was found to be positive for SARS-CoV-2 infection, but was not treated with hydroxychloroquine. Although AGEP has been described in association with some viral infections, it is more commonly a drug-associated dermatosis, commonly seen during treatment with antibiotics. As in this case, AGEP usually resolves after discontinuation of the offending antibiotic. International Scientific Literature, Inc. 2020-10-24 /pmc/articles/PMC7592336/ /pubmed/33097683 http://dx.doi.org/10.12659/AJCR.926901 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Haraszti, Samantha
Sendil, Selin
Jensen, Nichole
Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
title Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
title_full Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
title_fullStr Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
title_full_unstemmed Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
title_short Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
title_sort delayed presentation of acute generalized exanthematous pustulosis following treatment with cefepime in a patient with covid-19 without the use of hydroxychloroquine
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592336/
https://www.ncbi.nlm.nih.gov/pubmed/33097683
http://dx.doi.org/10.12659/AJCR.926901
work_keys_str_mv AT harasztisamantha delayedpresentationofacutegeneralizedexanthematouspustulosisfollowingtreatmentwithcefepimeinapatientwithcovid19withouttheuseofhydroxychloroquine
AT sendilselin delayedpresentationofacutegeneralizedexanthematouspustulosisfollowingtreatmentwithcefepimeinapatientwithcovid19withouttheuseofhydroxychloroquine
AT jensennichole delayedpresentationofacutegeneralizedexanthematouspustulosisfollowingtreatmentwithcefepimeinapatientwithcovid19withouttheuseofhydroxychloroquine